82 FR 16406 - National Heart, Lung, and Blood Institute; Notice of Closed Meeting

DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health

Federal Register Volume 82, Issue 63 (April 4, 2017)

Page Range		16406-16407
FR Document		2017-06551

Federal Register, Volume 82 Issue 63 (Tuesday, April 4, 2017)

[Federal Register Volume 82, Number 63 (Tuesday, April 4, 2017)]
[Notices]
[Pages 16406-16407]
From the Federal Register Online  [www.thefederalregister.org]
[FR Doc No: 2017-06551]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Heart, Lung, and Blood Institute; Notice of Closed 
Meeting

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as 
amended (5 U.S.C. App.), notice is hereby given of the following 
meeting.
    The meeting will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 
U.S.C., as amended. The grant applications and the discussions could 
disclose confidential trade secrets or commercial property such as 
patentable material, and personal information concerning individuals 
associated with the grant applications, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.


[[Page 16407]]


    Name of Committee: National Heart, Lung, and Blood Institute 
Special Emphasis Panel; Molecular Mechanisms of Ventilator-Induced 
Lung Injury.
    Date: April 27, 2017.
    Time: 10:00 a.m. to 12:30 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institutes of Health, 6701 Rockledge Drive, Room 
7206, Bethesda, MD 20892 (Telephone Conference Call).
    Contact Person: Shelley S Sehnert, Ph.D., Scientific Review 
Officer, Office of Scientific Review/DERA National Heart, Lung, and 
Blood Institute, 6701 Rockledge Drive, Room 7206, Bethesda, MD 
20892-7924, 301-435-0303, ssehnert@nhlbi.nih.gov.

(Catalogue of Federal Domestic Assistance Program Nos. 93.233, 
National Center for Sleep Disorders Research; 93.837, Heart and 
Vascular Diseases Research; 93.838, Lung Diseases Research; 93.839, 
Blood Diseases and Resources Research, National Institutes of 
Health, HHS)

    Dated: March 29, 2017.
Michelle Trout,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2017-06551 Filed 4-3-17; 8:45 am]
 BILLING CODE 4140-01-P

16406 Federal Register / Vol. 82, No. 63 / Tuesday, April 4, 2017 / Notices

of the contemplated Exclusive Patent Cancers With Elevated Levels Of Reactive elevated in many cancers. In addition,
License. Comments and objections to Oxygen Species (ROS) And/or Low Levels Of the prodrug and hybrid may have
this notice submitted will not be made Antioxidant Defense/DNA Repair synergy with therapeutics (such as
Mechanisms.’’
available for public inspection and, to (a) United States Provisional Patent
proteasome inhibitor bortezomib and
the extent permitted by law, will not be Application No. 61/261,175 filed November doxorubicin) which act through
released under the Freedom of 13, 2009; generation of ROS. Taken together, these
Information Act, 5 U.S.C. 552. (b) PCT Application No. PCT/US2010/ features suggest that the prodrug and
Dated: March 21, 2017. 056446 filed November 12, 2010; hybrid may have therapeutic
(c) United States Patent Application No. applications in cancer patients whose
Cristina Thalhammer-Reyero, 13/509,431 filed June 01, 2012, US Patent
Senior Licensing and Patenting Manager, tumors include high levels of ROS.
9,205,091 issued December 08, 2015;
Office of Technology Transfer and (d) Australian Patent Application No. This notice is made in accordance
Development, National Heart, Lung, and 2010319398 filed May 09, 2012; with 35 U.S.C. 209 and 37 CFR part 404.
Blood Institute. (e) Canadian Patent Application No. The prospective Start-up Exclusive
[FR Doc. 2017–06546 Filed 4–3–17; 8:45 am] 2,780,633 filed May 10, 2012; Evaluation Option License will be
BILLING CODE 4140–01–P (f) European Patent Application No. royalty bearing, and the prospective
10778814.3 filed May 14, 2012; exclusive license may be granted unless
(2) E–220–2011/0 entitled ‘‘Hybrid
within fifteen (15) days from the date of
Diazeniumdiolated Compounds,
DEPARTMENT OF HEALTH AND this published notice, the National
Pharmaceutical Compositions, And Method
HUMAN SERVICES Of Treating Cancer.’’ Cancer Institute receives written
(a) United States Provisional Patent evidence and argument that establishes
National Institutes of Health Application No. 61/549,862, filed October 21, that the grant of the license would not
2011; be consistent with the requirements of
Prospective Grant of Start-up (b) PCT Application No. PCT/US2012/
Exclusive Evaluation Option Patent 35 U.S.C. 209 and 37 CFR part 404.
060785 filed October 18, 2012;
License: ‘‘The Development and Use of (c) United States Patent Application No.
Complete applications for a license in
Diazeniumdiolated and Hybrid 14/352,096 filed April 16, 2014, US Patent the prospective field of use that are filed
Diazeniumdiolated Compounds for the 9,168,266 issued October 27, 2015; in response to this notice will be treated
Treatment of Ovarian Cancer in (d) Australian Patent Application No. as objections to the grant of the
Humans’’ 2012326105 filed April 14, 2014; contemplated Start-up Exclusive
(e) Canadian Patent Application No. Evaluation Option License Agreement.
AGENCY: National Institutes of Health, 2,852,682 filed April 14, 2014; Comments and objections submitted to
HHS. (f) European Patent Application No. this notice will not be made available
ACTION: Notice. 12841601.3 filed April 14, 2014, European
Patent 2768824 issued December 07, 2016;
for public inspection and, to the extent
(i) German Patent 602012026435.7 issued permitted by law, will not be released
SUMMARY: The National Cancer Institute,
December 07, 2016; under the Freedom of Information Act,
an institute of the National Institutes of
(ii) French Patent 2768824 issued 5 U.S.C. 552.
Health, Department of Health and
December 07, 2016; and Dated: March 21, 2017.
Human Services, is contemplating the (iii) UK Patent 2768824 issued December
grant of a Start-up Exclusive Evaluation 07, 2016. Richard U. Rodriguez,
Option License to practice the Associate Director, Technology Transfer
inventions embodied in the Patents and The patent rights in these inventions Center, National Cancer Institute.
Patent Applications listed in the have been assigned to the government of [FR Doc. 2017–06545 Filed 4–3–17; 8:45 am]
Supplementary Information section of the United States of America.
BILLING CODE 4140–01–P
this notice to Tar Meta Biosciences, Inc. The prospective exclusive license
(‘‘TarMeta’’) located in King of Prussia, territory may be worldwide and the
PA, USA. field of use may be limited to ‘‘The DEPARTMENT OF HEALTH AND
development and use of HUMAN SERVICES
DATES: Only written comments and/or
diazeniumdiolated and hybrid
applications for a license which are
diazeniumdiolated compounds for the National Institutes of Health
received by the National Cancer
treatment of ovarian cancer in humans.’’
Institute’s Technology Transfer Center The present inventions describe the National Heart, Lung, and Blood
on or before April 19, 2017 will be use of diazeniumdiolate-based nitric Institute; Notice of Closed Meeting
considered. oxide (NO)-releasing compounds
ADDRESSES: Requests for copies of the wherein the cancer cell has an elevated Pursuant to section 10(d) of the
patent application, inquiries, and level of reactive oxygen species (ROS), Federal Advisory Committee Act, as
comments relating to the contemplated as well as the use of hybrid prodrug amended (5 U.S.C. App.), notice is
Start-up Exclusive Evaluation Option molecules that combine a hereby given of the following meeting.
License should be directed to: Kathleen diazeniumdiolated compound and a The meeting will be closed to the
Higinbotham, Senior Technology poly(ADP-ribose) polymerase (PARP) public in accordance with the
Transfer Manager, NCI Technology inhibitor in cancer cells to produce provisions set forth in sections
Transfer Center, Riverside 5, Suite 400, synergistic effects, whether alone or as 552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
8490 Progress Dr., Frederick, MD 21701, an adjuvant for other therapies. The as amended. The grant applications and
asabaliauskas on DSK3SPTVN1PROD with NOTICES

Telephone: (301)-624–8775; Facsimile: hybrid prodrug is expected to enhance the discussions could disclose
(301)-631–3027 Email: higinbok@ cytotoxicity by creating DNA damage confidential trade secrets or commercial
mail.nih.gov. with NO and preventing its repair with property such as patentable material,
SUPPLEMENTARY INFORMATION: the PARP inhibitor. The prodrug and and personal information concerning
the hybrid are activated by glutathione individuals associated with the grant
Intellectual Property S-transferase and are predicted to be applications, the disclosure of which
(1) E–025–2010/0 entitled ‘‘Nitric Oxide- effective in cancers with reactive oxygen would constitute a clearly unwarranted
based Cancer Therapeutic Agents For Lung species (ROS), both of which are invasion of personal privacy.

VerDate Sep<11>2014 16:21 Apr 03, 2017 Jkt 241001 PO 00000 Frm 00073 Fmt 4703 Sfmt 4703 E:\FR\FM\04APN1.SGM 04APN1

Document Created: 2017-04-03 23:53:55
Document Modified: 2017-04-03 23:53:55

Category		Regulatory Information
Collection		Federal Register
sudoc Class		AE 2.7: GS 4.107: AE 2.106:
Publisher		Office of the Federal Register, National Archives and Records Administration
Section		Notices
Dates		April 27, 2017.
FR Citation		82 FR 16406

82 FR 16406 - National Heart, Lung, and Blood Institute; Notice of Closed Meeting

DEPARTMENT OF HEALTH AND HUMAN SERVICESNational Institutes of Health

Federal Register Volume 82, Issue 63 (April 4, 2017)

DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health